3166 results about "Secreted substance" patented technology

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and / or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and / or psoriasis are described.

PCT No. PCT / JP97 / 02310 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed Jul. 3, 1997 PCT Pub. No. WO98 / 01448 PCT Pub. Date Jan. 15, 1998This invention relates to novel purine derivatives of formula (I): where R2 and R9 are hydrocarbon groups, R6 is an amino group and R8 is a hydroxyl, or acyloxy group. These purine derivatives are effective at promoting secretion of interferon in patients, and can be used to treat diseases against which interferon is effective.

A device and method for treating bodily conduits involves the application of energy to the smooth muscle tissue of the conduit walls to reduce the bulk of smooth muscle tissue and mucus glands. The irradiation treatment of the smooth muscle tissue causes a reduction in the amount of smooth muscle tissue over time which increases the inner diameter of the body conduit for improved fluid flow and prevents smooth muscle spasms. The treatment is particularly useful in the lungs for treatment of asthma to prevent bronchospasms, increase the airway diameter for improved air exchange, and reduce mucus secretions in the lungs.

The invention provides methods employing iterative cycles of recombination and selection / screening for evolution of whole cells and organisms toward acquisition of desired properties Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and / or secretion of proteins and secondary metabolites.

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

The invention relates to the technical field of cosmetics, in particular to a natural plant extract composition and application thereof in the cosmetics. The natural plant extract composition is prepared from the following raw materials in parts by weight: 0.1 to 10 parts of plant stem cells, 2 to 10 parts of grapefruit extracts, 1 to 10 parts of radix asparagi extracting solution, 1 to 10 parts of gingko extracts, 5 to 10 parts of lucid ganoderma extracting solution, and 1 to 5 parts of burdock extracting solution. The natural plant extract composition provided by the invention not only has remarkable moisturizing and anti-aging effect, but also has the effects in removing acnes, adjusting grease secretion, resisting inflammation and relieving, and can be used for preparing moisturizing, anti-aging or acne-removing cosmetics.

Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.

A gastrointestinal implant device is positioned in a patient's small intestine or rectum and produces an outward force that itself produces a distension signal which is a therapeutically useful neural or humoral signal that evokes satiogenic or weight loss effects by itself. The device may advantageously be placed in the duodenum adjacent the pylorus or in the jejunum, ileum or rectum. The distension signals may amplify chemosensory or mechanosensory signals such as enteroendocrine secretions within the patient. The device may be a mesh and include a low material density that allows for unrestricted chyme absorption within the small intestine and unrestricted chyme flow through the gastrointestinal system. A method includes inserting the device into the patient then either retrieving the device after treatment is complete or allowing a device formed of a biodegradable material to degrade in time after treatment is complete.

A yeast alpha-factor expression system is provided comprised of a truncated leader sequence, containing the alpha-factor signal peptide and one glycosylation site, linked by a processing site to a non-yeast protein-encoding sequence.

Disclosed is a breast pump that supports a mother's and infant's breastfeeding needs and facilitates the lifestyle of the mother's choice. The breast milk expression system disclosed allows breastfeeding mothers to obtain milk comfortably, hands-free, conveniently and with discretion. The breast milk expression system disclosed includes at least two contact points which mimic hand-expression as well as infant suckling and effectively stimulate the secretion of oxytocin and prolactin to provide a healthy, safe and efficient breastfeeding session. The system disclosed has a gentle rhythmic massage means and is located a distance from the base of the nipple and massages in all quadrants of the breast. The rhythmic forward pressure is provided by a plurality of opposing pairs of expression bellows that move the milk from the lactiferous sinuses through the nipple pores, bio-mimicking the techniques of hand expression.

The invention discloses spicy coarse grain dried bean curd. The spicy coarse grain dried bean curd is prepared from the following raw materials in parts by weight: 90 to 100 parts of dried soybeans, 3 to 4 parts of oat, 3 to 4 parts of millet, 4 to 5 parts of sorghum, 4 to 5 parts of corns, 2 to 3 parts of mulberries, 2 to 3 parts of hawthorn, 2 to 3 parts of jujubes, 1 to 2 parts of calamus leaves, 1 to 2 parts of platycladus orientalis leaves, 2 to 3 parts of prepared rehmannia root, 1 to 2 parts of fructus amomi, 1 to 2 parts of rehmannia flower, 1 to 2 parts of loofah sponge, 2 to 3 parts of cassia bark, and 2 to 3 parts of rhodiola rosea. A variety of grains are added into the spicy coarse grain dried bean curd, so that a nutritionally balanced structure system is formed; a plurality of seasonings are added, so that the dried bean curd tastes spicy and is easily preferred by consumers; the healthcare components of a plurality of traditional Chinese medicines are added, so that the nutrition value of the dried bean curd is high; the finished dried bean curd is ready to eat, spicy, unique, rich in nutrients and chewy, has the effects of stimulating appetite, improving digestion, tonifying liver and kidney, tonifying spleen and stomach, cooling blood to stop bleeding, promoting the secretion of saliva or body fluid and lubricating intestines, and is the best healthcare food catering to the market and consumers.

Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160–400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5–20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.

A method and apparatus for treating gland dysfunction caused by gland obstruction in order to restore the natural flow of secretion from the gland comprises the application of a combination of energy, suction, vibration, heat, aspiration, chemical agents and pharmacological agents to loosen and thereafter remove the obstructive material'.

An inflatable system, of between one and three balloons, for cervical dilation and labor induction is provided. The inflatable system may have a uterine balloon, for positioning at a proximal portion of the uterus, with respect to an operator, adjacent to the cervical internal os, the uterine balloon being shaped so as to maximize the pressure against the decidua and the internal cervical os and so as to minimize the pressure on the fetal head. Additionally or alternatively, the inflatable system may have a vaginal balloon, for positioning in the vagina, for applying pressure on the external cervical os. Additionally or alternatively, the inflatable system may have a cervical balloon, for positioning in the cervical canal, the cervical balloon being shaped so as to maximize the contact area with the cervix. The balloons are operative to stimulate the secretion of hormone, by exerting pressure on the proximal decidual surfaces of the uterus and on the cervix, so as to soften and ripen the cervix, cause the cervix to dilate, and induce labor. The balloons, which may have rough external surfaces, in order to keep them anchored in place, may be inflated by the operator, directly after their insertion, or manually and gradually, by the woman herself. Various sensors and other instruments may be used with the inflatable system, to monitor cervical dilation, fetal well-being, and the woman's conditions.

The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient:(wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4).The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

Novel methods for identification of inhibitors or modulators of binding activities mediated by lectin domains of polypeptide GalNAc-transferases are disclosed. Direct binding activity of GalNAc-transferase lectins has been demonstrated for the first time and methods to measure lectin mediated binding of isolated lectins or enzymes with lectin domains are disclosed. The present invention specifically discloses a novel selective inhibitor of polypeptide GalNAc-transferase lectin domains, which provides a major advancement in that this inhibitor and related inhibitors sharing common characteristics of activity bind lectin domains without serving as acceptor substrate for glycosyltransferases involved in synthesis of O-glycans. This inhibitor is represented by the β-anomeric configuration of GalNAc-benzyl, GalNAcβ-benzyl. Methods for inhibiting intracellular transport, cell surface expression, and secretion of mucins and O-glycosylated glycoproteins without affecting O-glycosylation processing are disclosed using the novel selective inhibitor identified.

A pulmonary secretion clearing ventilation catheter and related airway management system is disclosed. The ventilation catheter has a double lumen portion which each lumen of the double lumen portion operably secured to an airway management system so that inspiratory fluid (air / oxygen mixtures, with or without added water vapor) is delivered to the distal end of the ventilation catheter through one of the two lumens and expired inspiratory fluid, pulmonary secretions, and pulmonary fluids are removed from the patent through the other lumen. The expiratory fluid pathway preferably includes a secretion collection system for removing the pulmonary secretions and the like from the pathway, thereby improving operation and safety of the system. An improved inflatable cuff is also disclosed that permits a slight air leakage in the pneumatic seal between the patient's lungs and the environment, thereby facilitating removal of pulmonary secretions from the patient's lungs.

The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The delivery vector comprises a segment encoding a secretory signal peptide. In embodiments of the invention, the delivery vector is an adeno-associated virus (AAV) vector. In other embodiments, the secretory signal peptide is a fibronectin secretory signal peptide (including variations and modifications, thereof). The delivery vectors of the invention may further comprise a heterologous nucleic acid sequence encoding a polypeptide of interest for transfer to a target cell, where the polypeptide of interest is operably associated with the secretory signal. Also disclosed are methods of transferring a nucleic acid of interest to a cell using the delivery vectors of the invention.

A device and method for treating bodily conduits involves the application of energy to the smooth muscle tissue of the conduit walls to reduce the bulk of smooth muscle tissue and mucus glands. The irradiation treatment of the smooth muscle tissue causes a reduction in the amount of smooth muscle tissue over time which increases the inner diameter of the body conduit for improved fluid flow and prevents smooth muscle spasms. The treatment is particularly useful in the lungs for treatment of asthma to prevent bronchospasms, increase the airway diameter for improved air exchange, and reduce mucus secretions in the lungs.

A continuous high-frequency oscillation breathing device delivers therapy during both inhalation and exhalation in order to assist in clearing secretions from the lungs. A fixed shrouded-venturi patient interface circuit is combined with medicated aerosol to deliver continuous high-frequency oscillation therapy. Fixed open apertures in the patient interface circuit allow ingress and egress of flow, and are calibrated to allow exhalation and prevent stacking of successive breaths.

Apparatus and methods are disclosed by which a closed ventilating system accommodates multiple access to the respiratory system of an intubated medical patient without compromising the closed character of the system. Access to the respiratory system through one or more access sites of the closed system apparatus is provided at proximal adapter ports to ventilate the lungs of the patient with gas or gases, to aspirate secretions from the lungs, to oxygenate the lungs to eliminate or reduce residual co2 therefrom, to visually inspect selected parts of the respiratory system, to sample sputum and gases, to sense parameters such as flow rates, pressure, and temperature, to flush with washing solution, and / or to administer medication, gases, and / or lavage. A distal swivel fitting provides multiple sealing sites by which entry of atmosphere is prevented.

Compositions and methods for improving expression and / or secretion of protein or polypeptide of interest in a host cell are provided. Compositions comprising a coding sequence for a bacterial secretion signal peptide are provided. The coding sequences can be used in vector constructs or expression systems for transformation and expression of a protein or polypeptide of interest in a host cell. The compositions of the invention are useful for increasing accumulation of properly processed proteins in the periplasmic space of a host cell, or for increasing secretion of properly processed proteins from the host cell. In particular, isolated secretion signal peptide-encoding nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the nucleic acid molecules are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24, and the nucleotide sequences set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, as well as variants and fragments thereof.

Apparatus and methods are disclosed by which a closed ventilating system accommodates multiple access to the respiratory system of an intubated medical patient without compromising the closed character of the system. Access to the respiratory system through one or more access sites of the closed system apparatus is provided at proximal adapter ports to ventilate the lungs of the patient with gas or gases, to aspirate secretions from the lungs, to oxygenate the lungs to eliminate or reduce residual co.sub.2 therefrom, to visually inspect selected parts of the respiratory system, to sample sputum and gases, to sense parameters such as flow rates, pressure, and temperature, to flush with washing solution, and / or to administer medication, gases, and / or lavage. A distal swivel fitting provides multiple sealing sites by which entry of atmosphere is prevented.

The present invention relates to a food contamination detector associated with a double bar code, given the trademark GILBAR.TM. by the owner of the present invention, that includes coded indicia used to identify the presence of conditions indicative of microbial contamination in food, including toxic contaminants, bacterial metabolites, and other microbial secretions. Of the two bar code symbols associated with the food contamination detector, the first identifies the food product in terms of the type of food, the quantity, the price and the like, while the second bar code symbol is designed to identify the presence of contaminants. When contamination is not detected, the first bar code symbol is scanner readable, whereas the second bar code symbol is not. Once contamination is detected, bars in both bar code symbols can appear or disappear causing the first bar code symbol to become scanner unreadable and the second bar code symbol to become scanner readable.